US · IMCR · BIOTECHNOLOGY
Immunocore Holdings plc (IMCR) intrinsic value and stock valuation
$26.41as of 2026-11-21 · Mkt cap 1.73B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Immunocore Holdings plc DCF and intrinsic value
InvestorsCraft values IMCR with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from IMCR’s statements →
Immunocore Holdings plc Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2013–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Celldex Therapeutics, Inc. (CLDX) $27.42
- Vera Therapeutics, Inc. (VERA) $25.45
- Sionna Therapeutics, Inc. (SION) $2.83
- Nuvation Bio Inc. (NUVB) $3.80
- Harmony Biosciences Holdings, Inc. (HRMY) $32.59
- Biohaven Ltd. (BHVN) $12.39
- AbCellera Biologics Inc. (ABCL) $9.69
- Xeris Biopharma Holdings, Inc. (XERS) $16.97
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $297.6M | $248M | $197.4M | $144.2M | $27M |
| Operating income | -$-33.74M | -$-56.28M | -$-47.2M | -$-42.77M | -$-129.42M |
| Net income | -$-26.42M | -$-40.81M | -$-43.75M | -$-43.46M | -$-133.45M |
| EPSd | -$-524.73K | -$-816.36K | -$-894.87K | -$-950.78K | -$-3.04M |
| Operating cash flow | -$-7.97M | $26.1M | $2.33M | -$-49.21M | -$-143.11M |
| Capital expenditure | -$-3.23M | -$-5.17M | -$-4.29M | -$-2.2M | -$-1.39M |
| Free cash flow | -$-11.2M | $20.9M | -$-1.97M | -$-51.41M | -$-144.49M |
| Total assets | $1.07B | $1.01B | $472.4M | $526.8M | $407.3M |
| Total debt | $436.7M | $432.7M | $66.5M | $81.5M | $86.2M |
| Net debt | -$-31.02M | -$-23.01M | -$-283.77M | -$-321.02M | -$-234.9M |
| Total equity | $381M | $360.7M | $291.9M | $338.9M | $231.5M |
| Cash and short-term investments | $864.2M | $820.4M | $350.3M | $402.5M | $321.1M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $297.6M | $248M | $197.4M | $144.2M | $27M |
| Cost of revenue | $6.21M | $5.54M | $820K | $5.29M | $0.00 |
| Gross profit | $291.4M | $242.4M | $196.6M | $138.9M | $27M |
| Research and development expenses | $204.5M | $177.4M | $129.4M | $84.3M | $74.3M |
| Selling, general and administrative expenses | $120.6M | $121.2M | $114.4M | $0.00 | $82.2M |
| Other expenses | $0.00 | $150K | $0.00 | $97.4M | $0.00 |
| Operating expenses | $325.1M | $298.8M | $243.8M | $181.7M | $156.5M |
| Cost and expenses | $331.3M | $304.3M | $244.6M | $187M | $156.5M |
| Interest income | $16.5M | $25.6M | $14.2M | $3.76M | $70K |
| Interest expense | $12.2M | $18.8M | $4.08M | $5.41M | $5.57M |
| Depreciation and amortization | $2.43M | $3.36M | $3.24M | $4.41M | $5.63M |
| Ebitda | $390K | -$-38.5M | -$-40.87M | -$-38.35M | -$-123.58M |
| Operating income | -$-33.74M | -$-56.28M | -$-47.2M | -$-42.77M | -$-129.42M |
| Total other income/expenses, net | $19.5M | $14M | -$-980K | $8.95M | -$-3.92M |
| Income before tax | -$-14.21M | -$-42.32M | -$-48.19M | -$-33.82M | -$-133.34M |
| Income tax expense | $12.2M | -$-1.48M | -$-4.43M | $9.65M | $110K |
| Net income | -$-26.42M | -$-40.81M | -$-43.75M | -$-43.46M | -$-133.45M |
| Weighted average shares outstanding | $50.4M | $50M | $48.9M | $45.7M | $42.5M |
| Weighted average diluted shares outstanding | $50.4M | $50M | $48.9M | $45.7M | $43.9M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $864.2M | $820.4M | $350.3M | $402.5M | $321.1M |
| Net receivables | $74M | $83.1M | $48.6M | $57.1M | $33.5M |
| Inventory | $6.74M | $5.45M | $3.56M | $690K | $0.00 |
| Total current assets | $996.7M | $929.9M | $418.5M | $474M | $354.6M |
| Property, plant and equipment, net | $50.2M | $47.7M | $33.8M | $38.8M | $42.6M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $140K | $220K |
| Total non-current assets | $70.5M | $79.6M | $54M | $52.8M | $52.7M |
| Total assets | $1.07B | $1.01B | $472.4M | $526.8M | $407.3M |
| Accounts payable | $24.4M | $25.1M | $14.1M | $14.5M | $10.1M |
| Short-term debt | $2.01M | $1.55M | $1.1M | $1.88M | $1.69M |
| Deferred revenue | $580K | $0.00 | $0.00 | $7.76M | $33M |
| Total current liabilities | $246.7M | $212.2M | $110M | $100.8M | $82.6M |
| Long-term debt | $434.7M | $431.2M | $65.4M | $79.6M | $84.5M |
| Deferred revenue, non-current | $4.86M | $5.43M | $4.36M | $5.24M | $8.65M |
| Total non-current liabilities | $439.5M | $436.6M | $70.5M | $87M | $93.2M |
| Capital lease obligations | $43.6M | $41.7M | $28.5M | $33.6M | $35.9M |
| Total liabilities | $686.2M | $648.8M | $180.6M | $187.9M | $175.8M |
| Common stock | $140K | $140K | $80K | $130K | $120K |
| Retained earnings | -$-831.27M | -$-795.76M | -$-589.3M | -$-689.39M | -$-649.7M |
| Accumulated other comprehensive income (loss) | -$-28.08M | -$-33.76M | -$-28.7M | -$-54.67M | $521.3M |
| Total equity | $381M | $360.7M | $291.9M | $338.9M | $231.5M |
| Total investments | $396.4M | $364.6M | $0.00 | $140K | $220K |
| Total debt | $436.7M | $432.7M | $66.5M | $81.5M | $86.2M |
| Net debt | -$-31.02M | -$-23.01M | -$-283.77M | -$-321.02M | -$-234.9M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-26.42M | -$-51.09M | -$-34.32M | -$-52.54M | -$-180.03M |
| Depreciation and amortization | $2.43M | $4.2M | $3.24M | $5.33M | $7.59M |
| Stock-based compensation | $0.00 | $34.2M | $25.7M | $32.9M | $48.9M |
| Change in working capital | -$-6.92M | $45.1M | $4.58M | -$-24.16M | -$-21.96M |
| Accounts receivable | -$-5.46M | -$-12.35M | -$-14.14M | -$-26.26M | -$-4.86M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-1.83M | $7.27M | $2.08M | $4.91M | $1.47M |
| Net cash provided by operating activities | -$-7.97M | $26.1M | $2.33M | -$-49.21M | -$-143.11M |
| Investments in property, plant and equipment | -$-3.23M | -$-5.17M | -$-3.37M | -$-2.2M | -$-1.39M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-12.16M | -$-355.13M | -$-4.29M | -$-2.2M | -$-1.28M |
| Common stock issued | $9.2M | $6.8M | $0.00 | $139.5M | $286.9M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $9.2M | $343.9M | $27.2M | $145.4M | $288.2M |
| Net change in cash | $8.89M | $13.1M | $31.8M | $81.4M | $144.4M |
| Cash at end of period | $347.1M | $455.7M | $350.3M | $402.5M | $321.1M |
| Operating cash flow | -$-7.97M | $26.1M | $2.33M | -$-49.21M | -$-143.11M |
| Capital expenditure | -$-3.23M | -$-5.17M | -$-4.29M | -$-2.2M | -$-1.39M |
| Free cash flow | -$-11.2M | $20.9M | -$-1.97M | -$-51.41M | -$-144.49M |
Line items
Line items
Line items
About Immunocore Holdings plc
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.
- CEO
- Bahija Jallal
- Employees
- 524
- Beta
- 0.73
Explore
Frequently asked questions
What is the intrinsic value of Immunocore Holdings plc (IMCR)?
Immunocore Holdings plc (IMCR) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is IMCR undervalued?
IMCR trades at a price of $26.41 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.